Industry Research Reports

Home > Reports > Service & Software > Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Service & Software

Published Date: 2026-08-14

Pages: 199 Pages

Report ld: 6991202

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

biaoTi KEY FINDINGS

Europe has the densest specialist supplier base, while North America combines major imaging platforms with leading neurovascular and surgical-planning vendors

Stroke and cerebrovascular imaging remain commercially established applications, while neurodegenerative monitoring is becoming a more important source of incremental demand

MRI-based quantification is expanding from diagnostic assessment toward treatment eligibility, longitudinal monitoring and ARIA evaluation

Neuroimaging Software Market Size(US$)

CAGR 2026-2032

10.3%

Market Size,2032

USD 2,638

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 1,466 million

Market Forecast in 2032(Value)

US$ 2,638 million

CAGR

10.3%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Neuroimaging Software market size was US$ 1326 million in 2025 and is forecast to reach a readjusted size of US$ 2638 million by 2032 with a CAGR of 10.3% during the forecast period 2026-2032.

Neuroimaging Software refers to specialized medical software used to process, quantify, visualize, interpret, and manage analytical outputs derived from imaging of the brain and central nervous system. The market primarily covers software applied to MRI and its advanced sequences, CT/CTA/CTP, PET, SPECT, and multimodal neuroimaging datasets. Core capabilities include image registration and correction, automated tissue and lesion segmentation, brain volumetry and morphometry, perfusion analysis, diffusion and tractography processing, functional brain mapping, molecular imaging quantification, longitudinal change assessment, AI-assisted abnormality detection, and structured reporting. Commercial products are delivered through on-premise workstations, server-based applications, cloud or SaaS platforms, identifiable advanced post-processing modules integrated into imaging environments, and specialized analytical platforms supporting clinical trials and neuroscience research. Neuroimaging Software is primarily used in stroke and cerebrovascular disease, Alzheimer’s disease and other neurodegenerative disorders, multiple sclerosis, neuro-oncology, epilepsy, neurosurgical planning, functional brain assessment, and CNS drug development. The market is characterized by a combination of regulated clinical software, specialized quantitative imaging tools, AI-enabled decision-support applications, and research-oriented commercial platforms.

biaoTi MARKET TRENDS

Neuroimaging Software is shifting from isolated post-processing tools and single-purpose algorithms toward integrated, multimodal and longitudinal analytical workflows. MRI remains central to quantitative brain analysis, while CT-based stroke applications, PET and SPECT quantification, diffusion imaging, functional MRI and multimodal fusion broaden the addressable clinical workflows. Product development is increasingly focused on automated segmentation, quantitative biomarkers, longitudinal comparison, structured reporting and cloud-enabled delivery rather than stand-alone visualization alone. The expansion of disease-modifying therapies for Alzheimer’s disease is also strengthening the role of quantitative MRI and treatment-safety monitoring. In August 2025, the U.S. FDA required an additional earlier MRI monitoring point for patients receiving lecanemab because of ARIA risk, reinforcing the importance of repeatable brain-image assessment during therapy. At the same time, consolidation is accelerating as larger imaging and digital-health groups acquire specialized analytical technologies: GE HealthCare completed its acquisition of icometrix in 2025, SyntheticMR completed its acquisition of Combinostics, and RadNet acquired Gleamer for integration into DeepHealth in March 2026.

MARKET SEGMENTATION

By Company

GE HealthCare
Siemens Healthineers
RapidAI
Viz.ai
Philips
Brainlab
Canon
Fujifilm
Brainomix
Bruker
Cortechs.ai
RadNet
Aidoc
ConcertAI
Qure.ai
United Imaging Intelligence
Shukun Technology
Infervision
Stryker
Nicolab
Avicenna.AI
Synaptive Medical
Quibim
Surgical Theater
mediaire
Qynapse
Thermo Fisher
Hermes Medical Solutions
Omniscient Neurotechnology
IQ-AI
Neurophet
LPIXEL
JLK
Brainreader
NordicNeuroLab
VUNO
Heuron
Coreline Soft
Cercare Medical

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Advanced Post-processing and Visualization
Quantitative Biomarkers and Volumetry
AI Detection
Molecular Neuroimaging Quantification
Others

Segment by Application

Stroke and Cerebrovascular Disease
Neurodegenerative Disease and Multiple Sclerosis
Neuro-oncology
Others

Segment by Category

On-premise
Cloud-based
Hybrid

Segment by Division

Clinical Diagnostic or Decision Support
Clinical Trial or Drug Development
Research Use Only
Others

biaoTi MARKET DYNAMICS

Drivers

Demand for Neuroimaging Software is being supported by the rising clinical need for faster and more standardized interpretation of complex neurological imaging, together with increasing use of quantitative biomarkers in stroke, dementia, multiple sclerosis, neuro-oncology and neurosurgical planning. Hospital systems are seeking tools that reduce manual measurement, improve consistency across readers and accelerate time-sensitive workflows, particularly in acute stroke. Another important driver is the growing role of imaging in treatment selection and safety monitoring for neurodegenerative therapies. FDA requirements for additional MRI monitoring during lecanemab therapy illustrate how imaging is becoming more closely connected to longitudinal therapeutic management rather than one-time diagnosis alone. CNS drug development also creates demand for standardized MRI and PET analysis across sites and time points, supporting specialized clinical-trial imaging and biomarker platforms.

Restraints

Market adoption remains constrained by fragmented reimbursement, lengthy hospital procurement cycles, regulatory requirements, interoperability issues and the cost of integrating analytical software into existing radiology and clinical workflows. Neuroimaging algorithms must also perform consistently across scanners, protocols, patient populations and imaging quality levels, increasing the cost of validation and product maintenance. In research-oriented applications, widely used academic and open-source software continues to limit pricing power for commercial vendors. Large imaging OEMs can also bundle advanced post-processing functions into broader workstation or enterprise-imaging contracts, which can reduce the addressable stand-alone software value for independent suppliers. These factors mean that technically strong products do not automatically translate into rapid commercial adoption, particularly where the clinical workflow benefit or reimbursement pathway is not clearly defined.

Opportunities

The most attractive opportunities are emerging where Neuroimaging Software moves beyond image visualization to support treatment pathways, measurable biomarkers and longitudinal disease management. Quantitative MRI for Alzheimer’s disease, ARIA assessment, automated brain volumetry, multiple-sclerosis monitoring, PET-based neurodegenerative biomarkers and treatment-response analysis are becoming increasingly relevant. CMS documentation on automated brain MRI detection and quantification identifies regulated commercial products for brain volumetry, ARIA analysis and morphometric assessment, demonstrating that these applications are moving toward identifiable clinical software categories. Additional opportunities exist in vendor-neutral cloud deployment, multimodal MRI/PET analysis, CNS clinical trials, smaller hospitals that lack specialist neuroradiology resources, and emerging Asian markets where domestic medical-AI suppliers are building localized neuroimaging products.

Challenges

The principal long-term challenge is converting algorithmic performance into repeatable clinical and economic value. Regulatory clearance alone does not guarantee reimbursement, workflow adoption or sustained usage, and suppliers must continuously demonstrate reliability across diverse populations and imaging environments. Competitive intensity is also rising as specialized algorithms become integrated into larger enterprise-imaging, AI-orchestration and scanner-vendor ecosystems. Consolidation may increase access to distribution while simultaneously reducing the number of independent purchasing decisions available to smaller vendors. Data privacy requirements, cross-border cloud deployment rules, cybersecurity expectations and evolving AI regulation add further complexity. The market therefore favors companies that can combine validated algorithms with clinical integration, scalable deployment, regulatory execution and durable relationships with hospitals or pharmaceutical customers.

biaoTi VALUE CHAIN ANALYSIS

The Neuroimaging Software value chain begins with medical imaging data, computational infrastructure, image-processing frameworks, anatomical atlases, clinically annotated datasets and algorithm-development capabilities. These inputs support the development of segmentation, registration, volumetric analysis, perfusion modeling, diffusion analysis, functional mapping, molecular imaging quantification and AI-based detection tools. The midstream layer consists of specialized software companies, medical-imaging OEMs, clinical AI developers, nuclear-medicine software providers, neurosurgical planning vendors and CNS imaging platforms. Products are commercialized through perpetual or term licenses, enterprise subscriptions, SaaS contracts, per-scan or usage-based models, OEM embedding arrangements and clinical-trial contracts.

Value is created when raw imaging data are converted into quantitative measurements, biomarkers, workflow prioritization, treatment-planning information or longitudinal evidence that improves decision consistency and reduces manual analytical work. Downstream users include hospitals, imaging centers, neurology and neurosurgery departments, pharmaceutical and biotechnology companies, CROs and research institutions. Cost structures are dominated by software R&D, clinical validation, regulatory compliance, data acquisition and curation, cloud infrastructure, cybersecurity, integration, sales and implementation. As deployment moves toward recurring SaaS and enterprise models, scalable software economics become more important, but clinical support, integration and regulatory maintenance remain meaningful cost components.

biaoTi SEGMENT INSIGHTS

From a product-function perspective, the market contains several commercially meaningful segments rather than a single homogeneous software category. Acute stroke and neurovascular analysis is one of the most established clinical applications because software outputs can be integrated directly into time-sensitive emergency workflows. Advanced post-processing and visualization also represent an established installed-base segment through major imaging vendors. Quantitative brain MRI, neurodegenerative disease assessment and longitudinal biomarker analysis are gaining strategic importance as neurological treatment pathways increasingly require repeatable measurements rather than qualitative interpretation alone. MRI-related applications represent the broadest product coverage across the identified supplier universe, spanning structural volumetry, diffusion imaging, functional mapping, perfusion, multiple-sclerosis analysis and neuro-oncology.

The fastest-evolving opportunity set is concentrated around quantitative and treatment-linked applications rather than basic image viewing. Automated brain segmentation, hippocampal and regional volumetry, cortical and lesion measurement, ARIA assessment and longitudinal change analysis are becoming increasingly differentiated commercial functions. CMS documentation recognizes multiple FDA-cleared products addressing automated labeling, visualization and volumetric quantification of brain MRI, as well as dedicated ARIA analysis, supporting the emergence of a more defined regulated quantitative-neuroimaging segment. Functional MRI, DTI, tractography, connectomics and molecular neuroimaging remain smaller but technically differentiated segments with strong relevance in neurosurgery, research and CNS drug development.

biaoTi DOWNSTREAM MARKET OPPORTUNITIES

Hospitals and diagnostic imaging centers remain the primary commercial users of Neuroimaging Software, but the demand profile is widening beyond the radiology department. Stroke centers require rapid neurovascular triage and perfusion analysis, neurology services increasingly use quantitative MRI for neurodegenerative and demyelinating diseases, and neurosurgical teams require multimodal fusion, tractography and functional mapping for preoperative planning. Pharmaceutical and biotechnology companies represent an increasingly strategic downstream opportunity because CNS drug programs depend on standardized longitudinal imaging biomarkers, patient stratification and safety monitoring. This creates room for software suppliers that can bridge routine clinical imaging and research-grade quantitative analysis. Smaller hospitals and imaging networks also represent an underpenetrated opportunity as cloud-based deployment reduces the need for dedicated local workstations and specialist post-processing resources.

biaoTi REGIONAL INSIGHTS

Fastest-Growing Region: Asia Pacific

Europe has the largest concentration of identified independent specialist Neuroimaging Software suppliers, particularly in quantitative brain MRI, perfusion, nuclear medicine, functional imaging and neurodegenerative disease analysis. The region combines established medical-imaging technology clusters with a relatively broad base of smaller specialist developers. North America has a different competitive structure: major imaging and digital-health platforms coexist with commercially advanced stroke-AI, neurosurgical planning, quantitative imaging and research-software providers. The region remains particularly important for regulated clinical commercialization because FDA clearance, large hospital networks and pharmaceutical demand can support broader deployment of successful products. CMS activity around automated brain MRI quantification also highlights increasing attention to the clinical and reimbursement framework for quantitative neuroimaging.

XX.X
%
CAGR*
XXXX
US$ Million
XXXX
REGIONAL SHARE

BY TYPE,2021-2032(US $ MILLION)

Advanced Post-processing and Visualization

Quantitative Biomarkers and Volumetry

AI Detection

Molecular Neuroimaging Quantification

Others

BY APPLICATION，2021-2032(US $ MILLION）

Stroke and Cerebrovascular Disease

Neurodegenerative Disease and Multiple Sclerosis

Neuro-oncology

Others

Asia-Pacific is becoming more strategically important but remains structurally fragmented. Japan combines global imaging OEMs with domestic neurological AI developers, while South Korea has developed a relatively dense cluster of specialist brain-imaging AI companies focused on volumetry, stroke, Parkinson’s disease, intracranial hemorrhage and cerebrovascular analysis. China has a growing medical-AI ecosystem, although the stricter product-evidence standard applied in this study results in a smaller Core Formal List than in Europe or North America. Taiwan and Australia contribute several niche vendors in diffusion MRI, brain metastasis analysis, perfusion and quantitative neuroimaging. The regional opportunity therefore lies less in simple geographic expansion and more in localization, regulatory approval, hospital integration and adaptation to country-specific clinical workflows.

biaoTi COMPETITIVE LANDSCAPE ANALYSIS

The Neuroimaging Software market has a layered competitive structure rather than a single group of directly comparable competitors. Major imaging OEMs compete through scanner installed bases, integrated workstations, enterprise-imaging relationships and global distribution, while independent specialists compete through deeper algorithms and clinical focus in stroke, brain volumetry, neurodegeneration, perfusion, molecular imaging, fMRI/DTI, neuro-oncology and neurosurgical planning. The study identifies 61 companies in the Core Formal List, demonstrating that the commercially relevant supplier base extends well beyond a small group of global imaging companies. Competitive consolidation is increasing as larger platforms acquire specialized software capabilities. GE HealthCare closed its acquisition of icometrix in 2025 to strengthen neurological MRI analysis, SyntheticMR acquired Combinostics to broaden quantitative neuroimaging capabilities, and RadNet acquired Gleamer in 2026 to expand DeepHealth’s clinical AI portfolio. These transactions point toward continued integration of specialist algorithms into broader imaging ecosystems, but highly differentiated areas such as ARIA quantification, connectomics, advanced perfusion, molecular imaging and functional brain mapping continue to provide defensible positions for focused vendors.

biaoTi REPORT SCOPE

The global Neuroimaging Software market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)

Chapter 2: Quantitative analysis of Neuroimaging Software market size and growth potential at global, regional, and country levels

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities

Chapter 6: Regional revenue breakdown by company, type, application and customer

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 9: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Neuroimaging Software value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032

1.2.2 Advanced Post-processing and Visualization

1.2.3 Quantitative Biomarkers and Volumetry

1.2.4 AI Detection

1.2.5 Molecular Neuroimaging Quantification

1.2.6 Others

1.3 Market by Application

1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032

1.3.2 Stroke and Cerebrovascular Disease

1.3.3 Neurodegenerative Disease and Multiple Sclerosis

1.3.4 Neuro-oncology

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuroimaging Software Market Perspective (2021-2032)

2.2 Global Market Size by Region: 2021 vs 2025 vs 2032

2.3 Global Neuroimaging Software Market Share by Revenue, by Region (2021-2026)

2.4 Global Neuroimaging Software Revenue Forecast by Region (2027-2032)

2.5 Major Regions and Emerging Markets Analysis

2.5.1 North America Neuroimaging Software Market Size and Prospective (2021-2032)

2.5.2 Europe Neuroimaging Software Market Size and Prospective (2021-2032)

2.5.3 Asia-Pacific Neuroimaging Software Market Size and Prospective (2021-2032)

2.5.4 Latin America Neuroimaging Software Market Size and Prospective (2021-2032)

2.5.5 Middle East & Africa Neuroimaging Software Market Size and Prospective (2021-2032)

3 Breakdown Data by Type

3.1 Global Neuroimaging Software Historical Market Size by Type (2021-2026)

3.2 Global Neuroimaging Software Forecasted Market Size by Type (2027-2032)

3.3 Representative Players for Different Types of Neuroimaging Software

4 Breakdown Data by Application

4.1 Global Neuroimaging Software Historical Market Size by Application (2021-2026)

4.2 Global Neuroimaging Software Forecasted Market Size by Application (2027-2032)

4.3 New Sources of Growth in Neuroimaging Software Applications

5 Competitive Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Neuroimaging Software Players by Revenue (2021-2026)

5.1.2 Global Neuroimaging Software Market Share by Revenue, by Players (2021-2026)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Neuroimaging Software Revenue

5.4 Global Neuroimaging Software Market Concentration Analysis

5.4.1 Global Neuroimaging Software Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Neuroimaging Software Revenue in 2025

5.5 Global Key Players of Neuroimaging Software Head Offices and Areas Served

5.6 Global Key Players of Neuroimaging Software, Product and Application

5.7 Global Key Players of Neuroimaging Software, Date of Entry into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Neuroimaging Software Revenue by Company (2021-2026)

6.1.2 North America Market Size by Type

6.1.2.1 North America Neuroimaging Software Market Size by Type (2021-2026)

6.1.2.2 North America Neuroimaging Software Market Share by Type (2021-2026)

6.1.3 North America Market Size by Application

6.1.3.1 North America Neuroimaging Software Market Size by Application (2021-2026)

6.1.3.2 North America Neuroimaging Software Market Share by Application (2021-2026)

6.1.4 North America Neuroimaging Software Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Neuroimaging Software Revenue by Company (2021-2026)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Neuroimaging Software Market Size by Type (2021-2026)

6.2.2.2 Europe Neuroimaging Software Market Share by Type (2021-2026)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Neuroimaging Software Market Size by Application (2021-2026)

6.2.3.2 Europe Neuroimaging Software Market Share by Application (2021-2026)

6.2.4 Europe Neuroimaging Software Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers

6.3.1 Asia-Pacific Neuroimaging Software Revenue by Company (2021-2026)

6.3.2 Asia-Pacific Market Size by Type

6.3.2.1 Asia-Pacific Neuroimaging Software Market Size by Type (2021-2026)

6.3.2.2 Asia-Pacific Neuroimaging Software Market Share by Type (2021-2026)

6.3.3 Asia-Pacific Market Size by Application

6.3.3.1 Asia-Pacific Neuroimaging Software Market Size by Application (2021-2026)

6.3.3.2 Asia-Pacific Neuroimaging Software Market Share by Application (2021-2026)

6.3.4 Asia-Pacific Neuroimaging Software Major Customers

6.3.5 Asia-Pacific Market Trends and Opportunities

6.4 Latin America Market: Players, Segments, Downstream and Major Customers

6.4.1 Latin America Neuroimaging Software Revenue by Company (2021-2026)

6.4.2 Latin America Market Size by Type

6.4.2.1 Latin America Neuroimaging Software Market Size by Type (2021-2026)

6.4.2.2 Latin America Neuroimaging Software Market Share by Type (2021-2026)

6.4.3 Latin America Market Size by Application

6.4.3.1 Latin America Neuroimaging Software Market Size by Application (2021-2026)

6.4.3.2 Latin America Neuroimaging Software Market Share by Application (2021-2026)

6.4.4 Latin America Neuroimaging Software Major Customers

6.4.5 Latin America Market Trends and Opportunities

6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers

6.5.1 Middle East & Africa Neuroimaging Software Revenue by Company (2021-2026)

6.5.2 Middle East & Africa Market Size by Type

6.5.2.1 Middle East & Africa Neuroimaging Software Market Size by Type (2021-2026)

6.5.2.2 Middle East & Africa Neuroimaging Software Market Share by Type (2021-2026)

6.5.3 Middle East & Africa Market Size by Application

6.5.3.1 Middle East & Africa Neuroimaging Software Market Size by Application (2021-2026)

6.5.3.2 Middle East & Africa Neuroimaging Software Market Share by Application (2021-2026)

6.5.4 Middle East & Africa Neuroimaging Software Major Customers

6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles

7.1 GE HealthCare

7.1.1 GE HealthCare Company Details

7.1.2 GE HealthCare Business Overview

7.1.3 GE HealthCare Neuroimaging Software Introduction

7.1.4 GE HealthCare Revenue in Neuroimaging Software Business (2021-2026)

7.1.5 GE HealthCare Recent Development

7.2 Siemens Healthineers

7.2.1 Siemens Healthineers Company Details

7.2.2 Siemens Healthineers Business Overview

7.2.3 Siemens Healthineers Neuroimaging Software Introduction

7.2.4 Siemens Healthineers Revenue in Neuroimaging Software Business (2021-2026)

7.2.5 Siemens Healthineers Recent Development

7.3 RapidAI

7.3.1 RapidAI Company Details

7.3.2 RapidAI Business Overview

7.3.3 RapidAI Neuroimaging Software Introduction

7.3.4 RapidAI Revenue in Neuroimaging Software Business (2021-2026)

7.3.5 RapidAI Recent Development

7.4 Viz.ai

7.4.1 Viz.ai Company Details

7.4.2 Viz.ai Business Overview

7.4.3 Viz.ai Neuroimaging Software Introduction

7.4.4 Viz.ai Revenue in Neuroimaging Software Business (2021-2026)

7.4.5 Viz.ai Recent Development

7.5 Philips

7.5.1 Philips Company Details

7.5.2 Philips Business Overview

7.5.3 Philips Neuroimaging Software Introduction

7.5.4 Philips Revenue in Neuroimaging Software Business (2021-2026)

7.5.5 Philips Recent Development

7.6 Brainlab

7.6.1 Brainlab Company Details

7.6.2 Brainlab Business Overview

7.6.3 Brainlab Neuroimaging Software Introduction

7.6.4 Brainlab Revenue in Neuroimaging Software Business (2021-2026)

7.6.5 Brainlab Recent Development

7.7 Canon

7.7.1 Canon Company Details

7.7.2 Canon Business Overview

7.7.3 Canon Neuroimaging Software Introduction

7.7.4 Canon Revenue in Neuroimaging Software Business (2021-2026)

7.7.5 Canon Recent Development

7.8 Fujifilm

7.8.1 Fujifilm Company Details

7.8.2 Fujifilm Business Overview

7.8.3 Fujifilm Neuroimaging Software Introduction

7.8.4 Fujifilm Revenue in Neuroimaging Software Business (2021-2026)

7.8.5 Fujifilm Recent Development

7.9 Brainomix

7.9.1 Brainomix Company Details

7.9.2 Brainomix Business Overview

7.9.3 Brainomix Neuroimaging Software Introduction

7.9.4 Brainomix Revenue in Neuroimaging Software Business (2021-2026)

7.9.5 Brainomix Recent Development

7.10 Bruker

7.10.1 Bruker Company Details

7.10.2 Bruker Business Overview

7.10.3 Bruker Neuroimaging Software Introduction

7.10.4 Bruker Revenue in Neuroimaging Software Business (2021-2026)

7.10.5 Bruker Recent Development

7.11 Cortechs.ai

7.11.1 Cortechs.ai Company Details

7.11.2 Cortechs.ai Business Overview

7.11.3 Cortechs.ai Neuroimaging Software Introduction

7.11.4 Cortechs.ai Revenue in Neuroimaging Software Business (2021-2026)

7.11.5 Cortechs.ai Recent Development

7.12 RadNet

7.12.1 RadNet Company Details

7.12.2 RadNet Business Overview

7.12.3 RadNet Neuroimaging Software Introduction

7.12.4 RadNet Revenue in Neuroimaging Software Business (2021-2026)

7.12.5 RadNet Recent Development

7.13 Aidoc

7.13.1 Aidoc Company Details

7.13.2 Aidoc Business Overview

7.13.3 Aidoc Neuroimaging Software Introduction

7.13.4 Aidoc Revenue in Neuroimaging Software Business (2021-2026)

7.13.5 Aidoc Recent Development

7.14 ConcertAI

7.14.1 ConcertAI Company Details

7.14.2 ConcertAI Business Overview

7.14.3 ConcertAI Neuroimaging Software Introduction

7.14.4 ConcertAI Revenue in Neuroimaging Software Business (2021-2026)

7.14.5 ConcertAI Recent Development

7.15 Qure.ai

7.15.1 Qure.ai Company Details

7.15.2 Qure.ai Business Overview

7.15.3 Qure.ai Neuroimaging Software Introduction

7.15.4 Qure.ai Revenue in Neuroimaging Software Business (2021-2026)

7.15.5 Qure.ai Recent Development

7.16 United Imaging Intelligence

7.16.1 United Imaging Intelligence Company Details

7.16.2 United Imaging Intelligence Business Overview

7.16.3 United Imaging Intelligence Neuroimaging Software Introduction

7.16.4 United Imaging Intelligence Revenue in Neuroimaging Software Business (2021-2026)

7.16.5 United Imaging Intelligence Recent Development

7.17 Shukun Technology

7.17.1 Shukun Technology Company Details

7.17.2 Shukun Technology Business Overview

7.17.3 Shukun Technology Neuroimaging Software Introduction

7.17.4 Shukun Technology Revenue in Neuroimaging Software Business (2021-2026)

7.17.5 Shukun Technology Recent Development

7.18 Infervision

7.18.1 Infervision Company Details

7.18.2 Infervision Business Overview

7.18.3 Infervision Neuroimaging Software Introduction

7.18.4 Infervision Revenue in Neuroimaging Software Business (2021-2026)

7.18.5 Infervision Recent Development

7.19 Stryker

7.19.1 Stryker Company Details

7.19.2 Stryker Business Overview

7.19.3 Stryker Neuroimaging Software Introduction

7.19.4 Stryker Revenue in Neuroimaging Software Business (2021-2026)

7.19.5 Stryker Recent Development

7.20 Nicolab

7.20.1 Nicolab Company Details

7.20.2 Nicolab Business Overview

7.20.3 Nicolab Neuroimaging Software Introduction

7.20.4 Nicolab Revenue in Neuroimaging Software Business (2021-2026)

7.20.5 Nicolab Recent Development

7.21 Avicenna.AI

7.21.1 Avicenna.AI Company Details

7.21.2 Avicenna.AI Business Overview

7.21.3 Avicenna.AI Neuroimaging Software Introduction

7.21.4 Avicenna.AI Revenue in Neuroimaging Software Business (2021-2026)

7.21.5 Avicenna.AI Recent Development

7.22 Synaptive Medical

7.22.1 Synaptive Medical Company Details

7.22.2 Synaptive Medical Business Overview

7.22.3 Synaptive Medical Neuroimaging Software Introduction

7.22.4 Synaptive Medical Revenue in Neuroimaging Software Business (2021-2026)

7.22.5 Synaptive Medical Recent Development

7.23 Quibim

7.23.1 Quibim Company Details

7.23.2 Quibim Business Overview

7.23.3 Quibim Neuroimaging Software Introduction

7.23.4 Quibim Revenue in Neuroimaging Software Business (2021-2026)

7.23.5 Quibim Recent Development

7.24 Surgical Theater

7.24.1 Surgical Theater Company Details

7.24.2 Surgical Theater Business Overview

7.24.3 Surgical Theater Neuroimaging Software Introduction

7.24.4 Surgical Theater Revenue in Neuroimaging Software Business (2021-2026)

7.24.5 Surgical Theater Recent Development

7.25 mediaire

7.25.1 mediaire Company Details

7.25.2 mediaire Business Overview

7.25.3 mediaire Neuroimaging Software Introduction

7.25.4 mediaire Revenue in Neuroimaging Software Business (2021-2026)

7.25.5 mediaire Recent Development

7.26 Qynapse

7.26.1 Qynapse Company Details

7.26.2 Qynapse Business Overview

7.26.3 Qynapse Neuroimaging Software Introduction

7.26.4 Qynapse Revenue in Neuroimaging Software Business (2021-2026)

7.26.5 Qynapse Recent Development

7.27 Thermo Fisher

7.27.1 Thermo Fisher Company Details

7.27.2 Thermo Fisher Business Overview

7.27.3 Thermo Fisher Neuroimaging Software Introduction

7.27.4 Thermo Fisher Revenue in Neuroimaging Software Business (2021-2026)

7.27.5 Thermo Fisher Recent Development

7.28 Hermes Medical Solutions

7.28.1 Hermes Medical Solutions Company Details

7.28.2 Hermes Medical Solutions Business Overview

7.28.3 Hermes Medical Solutions Neuroimaging Software Introduction

7.28.4 Hermes Medical Solutions Revenue in Neuroimaging Software Business (2021-2026)

7.28.5 Hermes Medical Solutions Recent Development

7.29 Omniscient Neurotechnology

7.29.1 Omniscient Neurotechnology Company Details

7.29.2 Omniscient Neurotechnology Business Overview

7.29.3 Omniscient Neurotechnology Neuroimaging Software Introduction

7.29.4 Omniscient Neurotechnology Revenue in Neuroimaging Software Business (2021-2026)

7.29.5 Omniscient Neurotechnology Recent Development

7.30 IQ-AI

7.30.1 IQ-AI Company Details

7.30.2 IQ-AI Business Overview

7.30.3 IQ-AI Neuroimaging Software Introduction

7.30.4 IQ-AI Revenue in Neuroimaging Software Business (2021-2026)

7.30.5 IQ-AI Recent Development

7.31 Neurophet

7.31.1 Neurophet Company Details

7.31.2 Neurophet Business Overview

7.31.3 Neurophet Neuroimaging Software Introduction

7.31.4 Neurophet Revenue in Neuroimaging Software Business (2021-2026)

7.31.5 Neurophet Recent Development

7.32 LPIXEL

7.32.1 LPIXEL Company Details

7.32.2 LPIXEL Business Overview

7.32.3 LPIXEL Neuroimaging Software Introduction

7.32.4 LPIXEL Revenue in Neuroimaging Software Business (2021-2026)

7.32.5 LPIXEL Recent Development

7.33 JLK

7.33.1 JLK Company Details

7.33.2 JLK Business Overview

7.33.3 JLK Neuroimaging Software Introduction

7.33.4 JLK Revenue in Neuroimaging Software Business (2021-2026)

7.33.5 JLK Recent Development

7.34 Brainreader

7.34.1 Brainreader Company Details

7.34.2 Brainreader Business Overview

7.34.3 Brainreader Neuroimaging Software Introduction

7.34.4 Brainreader Revenue in Neuroimaging Software Business (2021-2026)

7.34.5 Brainreader Recent Development

7.35 NordicNeuroLab

7.35.1 NordicNeuroLab Company Details

7.35.2 NordicNeuroLab Business Overview

7.35.3 NordicNeuroLab Neuroimaging Software Introduction

7.35.4 NordicNeuroLab Revenue in Neuroimaging Software Business (2021-2026)

7.35.5 NordicNeuroLab Recent Development

7.36 VUNO

7.36.1 VUNO Company Details

7.36.2 VUNO Business Overview

7.36.3 VUNO Neuroimaging Software Introduction

7.36.4 VUNO Revenue in Neuroimaging Software Business (2021-2026)

7.36.5 VUNO Recent Development

7.37 Heuron

7.37.1 Heuron Company Details

7.37.2 Heuron Business Overview

7.37.3 Heuron Neuroimaging Software Introduction

7.37.4 Heuron Revenue in Neuroimaging Software Business (2021-2026)

7.37.5 Heuron Recent Development

7.38 Coreline Soft

7.38.1 Coreline Soft Company Details

7.38.2 Coreline Soft Business Overview

7.38.3 Coreline Soft Neuroimaging Software Introduction

7.38.4 Coreline Soft Revenue in Neuroimaging Software Business (2021-2026)

7.38.5 Coreline Soft Recent Development

7.39 Cercare Medical

7.39.1 Cercare Medical Company Details

7.39.2 Cercare Medical Business Overview

7.39.3 Cercare Medical Neuroimaging Software Introduction

7.39.4 Cercare Medical Revenue in Neuroimaging Software Business (2021-2026)

7.39.5 Cercare Medical Recent Development

8 Neuroimaging Software Market Dynamics

8.1 Neuroimaging Software Industry Trends

8.2 Neuroimaging Software Market Drivers

8.3 Neuroimaging Software Market Challenges

8.4 Neuroimaging Software Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Neuroimaging Software Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Global Neuroimaging Software Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 3. Global Market Neuroimaging Software Market Size (US$ Million) by Region:2021 vs 2025 vs 2032

Table 4. Global Neuroimaging Software Revenue (US$ Million) Market Share by Region (2021-2026)

Table 5. Global Neuroimaging Software Revenue Share by Region (2021-2026)

Table 6. Global Neuroimaging Software Revenue (US$ Million) Forecast by Region (2027-2032)

Table 7. Global Neuroimaging Software Revenue Share Forecast by Region (2027-2032)

Table 8. Global Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 9. Global Neuroimaging Software Market Share by Revenue, by Type (2021-2026)

Table 10. Global Neuroimaging Software Forecasted Market Size by Type (2027-2032) & (US$ Million)

Table 11. Global Neuroimaging Software Market Share by Revenue, by Type (2027-2032)

Table 12. Representative Players of Each Type

Table 13. Global Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 14. Global Neuroimaging Software Market Share by Revenue, by Application (2021-2026)

Table 15. Global Neuroimaging Software Forecasted Market Size by Application (2027-2032) & (US$ Million)

Table 16. Global Neuroimaging Software Market Share by Revenue, by Application (2027-2032)

Table 17. New Sources of Growth in Neuroimaging Software Applications

Table 18. Global Neuroimaging Software Revenue by Players (2021-2026) & (US$ Million)

Table 19. Global Neuroimaging Software Market Share by Players (2021-2026)

Table 20. Global Top Neuroimaging Software Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroimaging Software as of 2025)

Table 21. Ranking of Global Top Neuroimaging Software Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Neuroimaging Software Revenue (CR5 and HHI) & (2021-2026)

Table 23. Global Key Players of Neuroimaging Software, Headquarters and Area Served

Table 24. Global Key Players of Neuroimaging Software, Product and Application

Table 25. Global Key Players of Neuroimaging Software, Date of Entry into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Neuroimaging Software Revenue by Company (2021-2026) & (US$ Million)

Table 28. North America Neuroimaging Software Market Share by Revenue, by Company (2021-2026)

Table 29. North America Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 30. North America Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 31. Europe Neuroimaging Software Revenue by Company (2021-2026) & (US$ Million)

Table 32. Europe Neuroimaging Software Market Share by Revenue, by Company (2021-2026)

Table 33. Europe Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 34. Europe Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 35. Asia-Pacific Neuroimaging Software Revenue by Company (2021-2026) & (US$ Million)

Table 36. Asia-Pacific Neuroimaging Software Market Share by Revenue, by Company (2021-2026)

Table 37. Asia-Pacific Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 38. Asia-Pacific Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 39. Latin America Neuroimaging Software Revenue by Company (2021-2026) & (US$ Million)

Table 40. Latin America Neuroimaging Software Market Share by Revenue, by Company (2021-2026)

Table 41. Latin America Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 42. Latin America Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 43. Middle East & Africa Neuroimaging Software Revenue by Company (2021-2026) & (US$ Million)

Table 44. Middle East & Africa Neuroimaging Software Market Share by Revenue, by Company (2021-2026)

Table 45. Middle East & Africa Neuroimaging Software Market Size by Type (2021-2026) & (US$ Million)

Table 46. Middle East & Africa Neuroimaging Software Market Size by Application (2021-2026) & (US$ Million)

Table 47. GE HealthCare Company Details

Table 48. GE HealthCare Business Overview

Table 49. GE HealthCare Neuroimaging Software Product

Table 50. GE HealthCare Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 51. GE HealthCare Recent Development

Table 52. Siemens Healthineers Company Details

Table 53. Siemens Healthineers Business Overview

Table 54. Siemens Healthineers Neuroimaging Software Product

Table 55. Siemens Healthineers Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 56. Siemens Healthineers Recent Development

Table 57. RapidAI Company Details

Table 58. RapidAI Business Overview

Table 59. RapidAI Neuroimaging Software Product

Table 60. RapidAI Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 61. RapidAI Recent Development

Table 62. Viz.ai Company Details

Table 63. Viz.ai Business Overview

Table 64. Viz.ai Neuroimaging Software Product

Table 65. Viz.ai Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 66. Viz.ai Recent Development

Table 67. Philips Company Details

Table 68. Philips Business Overview

Table 69. Philips Neuroimaging Software Product

Table 70. Philips Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 71. Philips Recent Development

Table 72. Brainlab Company Details

Table 73. Brainlab Business Overview

Table 74. Brainlab Neuroimaging Software Product

Table 75. Brainlab Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 76. Brainlab Recent Development

Table 77. Canon Company Details

Table 78. Canon Business Overview

Table 79. Canon Neuroimaging Software Product

Table 80. Canon Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 81. Canon Recent Development

Table 82. Fujifilm Company Details

Table 83. Fujifilm Business Overview

Table 84. Fujifilm Neuroimaging Software Product

Table 85. Fujifilm Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 86. Fujifilm Recent Development

Table 87. Brainomix Company Details

Table 88. Brainomix Business Overview

Table 89. Brainomix Neuroimaging Software Product

Table 90. Brainomix Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 91. Brainomix Recent Development

Table 92. Bruker Company Details

Table 93. Bruker Business Overview

Table 94. Bruker Neuroimaging Software Product

Table 95. Bruker Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 96. Bruker Recent Development

Table 97. Cortechs.ai Company Details

Table 98. Cortechs.ai Business Overview

Table 99. Cortechs.ai Neuroimaging Software Product

Table 100. Cortechs.ai Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 101. Cortechs.ai Recent Development

Table 102. RadNet Company Details

Table 103. RadNet Business Overview

Table 104. RadNet Neuroimaging Software Product

Table 105. RadNet Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 106. RadNet Recent Development

Table 107. Aidoc Company Details

Table 108. Aidoc Business Overview

Table 109. Aidoc Neuroimaging Software Product

Table 110. Aidoc Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 111. Aidoc Recent Development

Table 112. ConcertAI Company Details

Table 113. ConcertAI Business Overview

Table 114. ConcertAI Neuroimaging Software Product

Table 115. ConcertAI Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 116. ConcertAI Recent Development

Table 117. Qure.ai Company Details

Table 118. Qure.ai Business Overview

Table 119. Qure.ai Neuroimaging Software Product

Table 120. Qure.ai Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 121. Qure.ai Recent Development

Table 122. United Imaging Intelligence Company Details

Table 123. United Imaging Intelligence Business Overview

Table 124. United Imaging Intelligence Neuroimaging Software Product

Table 125. United Imaging Intelligence Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 126. United Imaging Intelligence Recent Development

Table 127. Shukun Technology Company Details

Table 128. Shukun Technology Business Overview

Table 129. Shukun Technology Neuroimaging Software Product

Table 130. Shukun Technology Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 131. Shukun Technology Recent Development

Table 132. Infervision Company Details

Table 133. Infervision Business Overview

Table 134. Infervision Neuroimaging Software Product

Table 135. Infervision Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 136. Infervision Recent Development

Table 137. Stryker Company Details

Table 138. Stryker Business Overview

Table 139. Stryker Neuroimaging Software Product

Table 140. Stryker Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 141. Stryker Recent Development

Table 142. Nicolab Company Details

Table 143. Nicolab Business Overview

Table 144. Nicolab Neuroimaging Software Product

Table 145. Nicolab Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 146. Nicolab Recent Development

Table 147. Avicenna.AI Company Details

Table 148. Avicenna.AI Business Overview

Table 149. Avicenna.AI Neuroimaging Software Product

Table 150. Avicenna.AI Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 151. Avicenna.AI Recent Development

Table 152. Synaptive Medical Company Details

Table 153. Synaptive Medical Business Overview

Table 154. Synaptive Medical Neuroimaging Software Product

Table 155. Synaptive Medical Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 156. Synaptive Medical Recent Development

Table 157. Quibim Company Details

Table 158. Quibim Business Overview

Table 159. Quibim Neuroimaging Software Product

Table 160. Quibim Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 161. Quibim Recent Development

Table 162. Surgical Theater Company Details

Table 163. Surgical Theater Business Overview

Table 164. Surgical Theater Neuroimaging Software Product

Table 165. Surgical Theater Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 166. Surgical Theater Recent Development

Table 167. mediaire Company Details

Table 168. mediaire Business Overview

Table 169. mediaire Neuroimaging Software Product

Table 170. mediaire Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 171. mediaire Recent Development

Table 172. Qynapse Company Details

Table 173. Qynapse Business Overview

Table 174. Qynapse Neuroimaging Software Product

Table 175. Qynapse Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 176. Qynapse Recent Development

Table 177. Thermo Fisher Company Details

Table 178. Thermo Fisher Business Overview

Table 179. Thermo Fisher Neuroimaging Software Product

Table 180. Thermo Fisher Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 181. Thermo Fisher Recent Development

Table 182. Hermes Medical Solutions Company Details

Table 183. Hermes Medical Solutions Business Overview

Table 184. Hermes Medical Solutions Neuroimaging Software Product

Table 185. Hermes Medical Solutions Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 186. Hermes Medical Solutions Recent Development

Table 187. Omniscient Neurotechnology Company Details

Table 188. Omniscient Neurotechnology Business Overview

Table 189. Omniscient Neurotechnology Neuroimaging Software Product

Table 190. Omniscient Neurotechnology Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 191. Omniscient Neurotechnology Recent Development

Table 192. IQ-AI Company Details

Table 193. IQ-AI Business Overview

Table 194. IQ-AI Neuroimaging Software Product

Table 195. IQ-AI Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 196. IQ-AI Recent Development

Table 197. Neurophet Company Details

Table 198. Neurophet Business Overview

Table 199. Neurophet Neuroimaging Software Product

Table 200. Neurophet Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 201. Neurophet Recent Development

Table 202. LPIXEL Company Details

Table 203. LPIXEL Business Overview

Table 204. LPIXEL Neuroimaging Software Product

Table 205. LPIXEL Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 206. LPIXEL Recent Development

Table 207. JLK Company Details

Table 208. JLK Business Overview

Table 209. JLK Neuroimaging Software Product

Table 210. JLK Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 211. JLK Recent Development

Table 212. Brainreader Company Details

Table 213. Brainreader Business Overview

Table 214. Brainreader Neuroimaging Software Product

Table 215. Brainreader Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 216. Brainreader Recent Development

Table 217. NordicNeuroLab Company Details

Table 218. NordicNeuroLab Business Overview

Table 219. NordicNeuroLab Neuroimaging Software Product

Table 220. NordicNeuroLab Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 221. NordicNeuroLab Recent Development

Table 222. VUNO Company Details

Table 223. VUNO Business Overview

Table 224. VUNO Neuroimaging Software Product

Table 225. VUNO Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 226. VUNO Recent Development

Table 227. Heuron Company Details

Table 228. Heuron Business Overview

Table 229. Heuron Neuroimaging Software Product

Table 230. Heuron Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 231. Heuron Recent Development

Table 232. Coreline Soft Company Details

Table 233. Coreline Soft Business Overview

Table 234. Coreline Soft Neuroimaging Software Product

Table 235. Coreline Soft Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 236. Coreline Soft Recent Development

Table 237. Cercare Medical Company Details

Table 238. Cercare Medical Business Overview

Table 239. Cercare Medical Neuroimaging Software Product

Table 240. Cercare Medical Revenue in Neuroimaging Software Business (2021-2026) & (US$ Million)

Table 241. Cercare Medical Recent Development

Table 242. Neuroimaging Software Market Trends

Table 243. Neuroimaging Software Market Drivers

Table 244. Neuroimaging Software Market Challenges

Table 245. Neuroimaging Software Market Restraints

Table 246. Research Programs/Design for This Report

Table 247. Key Data Information from Secondary Sources

Table 248. Key Data Information from Primary Sources

List of Figures

Figure 1. Neuroimaging Software Product Picture

Figure 2. Global Neuroimaging Software Market Share by Type: 2025 vs 2032

Figure 3. Advanced Post-processing and Visualization Features

Figure 4. Quantitative Biomarkers and Volumetry Features

Figure 5. AI Detection Features

Figure 6. Molecular Neuroimaging Quantification Features

Figure 7. Others Features

Figure 8. Global Neuroimaging Software Market Share by Application: 2025 vs 2032

Figure 9. Stroke and Cerebrovascular Disease

Figure 10. Neurodegenerative Disease and Multiple Sclerosis

Figure 11. Neuro-oncology

Figure 12. Others

Figure 13. Neuroimaging Software Report Years Considered

Figure 14. Global Neuroimaging Software Market Size (US$ Million), Year-over-Year: 2021-2032

Figure 15. Global Neuroimaging Software Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Neuroimaging Software Market Share by Revenue, by Region: 2021 vs 2025

Figure 17. North America Neuroimaging Software Revenue (US$ Million) Growth Rate (2021-2032)

Figure 18. Europe Neuroimaging Software Revenue (US$ Million) Growth Rate (2021-2032)

Figure 19. Asia-Pacific Neuroimaging Software Revenue (US$ Million) Growth Rate (2021-2032)

Figure 20. Latin America Neuroimaging Software Revenue (US$ Million) Growth Rate (2021-2032)

Figure 21. Middle East & Africa Neuroimaging Software Revenue (US$ Million) Growth Rate (2021-2032)

Figure 22. Global Neuroimaging Software Market Share by Players in 2025

Figure 23. Global Top Neuroimaging Software Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroimaging Software as of 2025)

Figure 24. The Top 10 and 5 Players Market Share by Neuroimaging Software Revenue in 2025

Figure 25. North America Neuroimaging Software Market Share by Type (2021-2026)

Figure 26. North America Neuroimaging Software Market Share by Application (2021-2026)

Figure 27. Europe Neuroimaging Software Market Share by Type (2021-2026)

Figure 28. Europe Neuroimaging Software Market Share by Application (2021-2026)

Figure 29. Asia-Pacific Neuroimaging Software Market Share by Type (2021-2026)

Figure 30. Asia-Pacific Neuroimaging Software Market Share by Application (2021-2026)

Figure 31. Latin America Neuroimaging Software Market Share by Type (2021-2026)

Figure 32. Latin America Neuroimaging Software Market Share by Application (2021-2026)

Figure 33. Middle East & Africa Neuroimaging Software Market Share by Type (2021-2026)

Figure 34. Middle East & Africa Neuroimaging Software Market Share by Application (2021-2026)

Figure 35. GE HealthCare Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 36. Siemens Healthineers Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 37. RapidAI Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 38. Viz.ai Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 39. Philips Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 40. Brainlab Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 41. Canon Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 42. Fujifilm Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 43. Brainomix Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 44. Bruker Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 45. Cortechs.ai Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 46. RadNet Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 47. Aidoc Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 48. ConcertAI Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 49. Qure.ai Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 50. United Imaging Intelligence Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 51. Shukun Technology Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 52. Infervision Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 53. Stryker Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 54. Nicolab Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 55. Avicenna.AI Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 56. Synaptive Medical Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 57. Quibim Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 58. Surgical Theater Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 59. mediaire Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 60. Qynapse Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 61. Thermo Fisher Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 62. Hermes Medical Solutions Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 63. Omniscient Neurotechnology Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 64. IQ-AI Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 65. Neurophet Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 66. LPIXEL Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 67. JLK Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 68. Brainreader Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 69. NordicNeuroLab Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 70. VUNO Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 71. Heuron Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 72. Coreline Soft Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 73. Cercare Medical Revenue Growth Rate in Neuroimaging Software Business (2021-2026)

Figure 74. Bottom-up and Top-down Approaches for This Report

Figure 75. Data Triangulation

Figure 76. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Neuroimaging Software market? zhanKai

The top companies in the global Neuroimaging Software market are GE HealthCare、Siemens Healthineers、RapidAI.

Which region is expected to have the highest market share? shouQi

What was the global market size of Neuroimaging Software in 2032? shouQi

What was the global market size of Neuroimaging Software in 2026? shouQi

What is the annual compound growth rate of the global Neuroimaging Software market size from 2026 to 2032? shouQi

Related Reports

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-08-14
Pages: 208
USD 4900.00
(Single User License)
Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neuroimaging Software was estimated to be worth US$ 1326 million in 2025 and is projected to reach US$ 2638 million, growing at a CAGR of 10.3% from 2026 to 2032.
Published Date: 2026-08-14
Pages: 206
USD 3950.00
(Single User License)
Global Neuroimaging Software Market Research Report 2026
The global Neuroimaging Software market was valued at US$ 1326 million in 2025 and is anticipated to reach US$ 2638 million by 2032, at a CAGR of 10.3% from 2026 to 2032.
Published Date: 2026-08-14
Pages: 209
USD 2900.00
(Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-17
Pages: 76
USD 4250.00
(Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-16
Pages: 130
USD 4900.00
(Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-04
Pages: 75
USD 2900.00
(Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-04
Pages: 95
USD 3950.00
(Single User License)

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-08-14
Pages: 208
USD 4900.00 (Single User License)
Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neuroimaging Software was estimated to be worth US$ 1326 million in 2025 and is projected to reach US$ 2638 million, growing at a CAGR of 10.3% from 2026 to 2032.
Published: 2026-08-14
Pages: 206
USD 3950.00 (Single User License)
Global Neuroimaging Software Market Research Report 2026
The global Neuroimaging Software market was valued at US$ 1326 million in 2025 and is anticipated to reach US$ 2638 million by 2032, at a CAGR of 10.3% from 2026 to 2032.
Published: 2026-08-14
Pages: 209
USD 2900.00 (Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-17
Pages: 76
USD 4250.00 (Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-16
Pages: 130
USD 4900.00 (Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-04
Pages: 75
USD 2900.00 (Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-04
Pages: 95
USD 3950.00 (Single User License)